Gilead’s Bad Luck In NASH Continues With ATLAS Failure

 
• By Joseph Haas

None of the two-drug combinations tested by Gilead met statistical significance in the multi-arm non-alcoholic steatohepatitis trial. This follows the Phase III failure of selonsertib monotherapy earlier in 2019.

Render illustration of Clinical Trial title on medical documents
ATLAS yields another NASH R&D setback for Gilead

More from Clinical Trials

More from R&D